Ko Toshiyuki, Nomura Seitaro
Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Front Cell Dev Biol. 2022 Jul 11;10:929256. doi: 10.3389/fcell.2022.929256. eCollection 2022.
Pathological heart injuries such as myocardial infarction induce adverse ventricular remodeling and progression to heart failure owing to widespread cardiomyocyte death. The adult mammalian heart is terminally differentiated unlike those of lower vertebrates. Therefore, the proliferative capacity of adult cardiomyocytes is limited and insufficient to restore an injured heart. Although current therapeutic approaches can delay progressive remodeling and heart failure, difficulties with the direct replenishment of lost cardiomyocytes results in a poor long-term prognosis for patients with heart failure. However, it has been revealed that cardiac function can be improved by regulating the cell cycle or changing the cell state of cardiomyocytes by delivering specific genes or small molecules. Therefore, manipulation of cardiomyocyte plasticity can be an effective treatment for heart disease. This review summarizes the recent studies that control heart regeneration by manipulating cardiomyocyte plasticity with various approaches including differentiating pluripotent stem cells into cardiomyocytes, reprogramming cardiac fibroblasts into cardiomyocytes, and reactivating the proliferation of cardiomyocytes.
诸如心肌梗死之类的病理性心脏损伤会导致广泛的心肌细胞死亡,进而引发不良的心室重构并进展为心力衰竭。与低等脊椎动物不同,成年哺乳动物的心脏是终末分化的。因此,成年心肌细胞的增殖能力有限,不足以修复受损的心脏。尽管目前的治疗方法可以延缓进行性重构和心力衰竭,但直接补充丢失的心肌细胞存在困难,导致心力衰竭患者的长期预后较差。然而,研究发现,通过递送特定基因或小分子来调节细胞周期或改变心肌细胞的细胞状态,可以改善心脏功能。因此,操纵心肌细胞可塑性可能是治疗心脏病的有效方法。本综述总结了最近的研究,这些研究通过多种方法操纵心肌细胞可塑性来控制心脏再生,包括将多能干细胞分化为心肌细胞、将心脏成纤维细胞重编程为心肌细胞以及重新激活心肌细胞的增殖。